Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT07052032
PHASE1
An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis
Sponsor: Candid Therapeutics
View on ClinicalTrials.gov
Summary
The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.
Official title: A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients With Seropositive Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2025-06-16
Completion Date
2027-06-01
Last Updated
2026-09-03
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
CND261
CND261 will be dosed according to the assigned cohort
Locations (2)
Candid Clinical Site
Chisinau, Moldova
Candid Clinical Site
Kyiv, Ukraine